This Week in GLP-1: Apotex Clears FDA, Novo Cuts Wegovy, and Canada’s Generic Pricing Framework
Here's what happened this week in GLP-1 medications in Canada. A Canadian company cleared a major regulatory hurdle, Novo Nordisk dramatically cut US Wegovy pricing, and the pan-Canadian Pharmaceutical Alliance laid the groundwork for generic pricing.
Apotex Wins First-Ever FDA Tentative Approval for Generic Ozempic
This is the biggest GLP-1 story of the week. Canadian generic manufacturer Apotex — in partnership with India's Orbicular Pharmaceutical Technologies — has received the first-ever tentative FDA approval for a generic version of semaglutide injection (the active ingredient in Ozempic).
"Tentative approval" means the FDA confirmed the generic meets all safety, quality, and efficacy standards — but it can't be sold in the US until Ozempic's patent protections expire in the early 2030s. The core composition patent extends to December 2031, with additional patents running through 2033. Being first in line gives Apotex 180 days of US market exclusivity when that day comes.
Canada angle: Here's what matters for us: Apotex has three separate applications pending with Health Canada — filed in January, April, and November 2025 — where there are no patent barriers remaining. Semaglutide's data exclusivity in Canada expired on January 5, 2026. This FDA validation is a strong signal that Apotex's manufacturing and quality standards are ready — and Health Canada is reviewing its applications now.
Canada's Generic Pricing Rules: What They Mean for Semaglutide
With nine generic semaglutide applications now under Health Canada review, it's worth understanding how pricing will work once approvals start rolling in.
Under Canada's established generic pricing framework — negotiated through the pan-Canadian Pharmaceutical Alliance (pCPA) — the first generic to market typically enters at 75–85% of the brand price. When a second generic arrives, that drops to around 50%. With three or more competitors, prices can fall to roughly 35% of the original.
Given that nine companies are in the queue — including Apotex (three applications), Sandoz, Teva, Taro, Aspen, Dr. Reddy's, and Vimy Pharma — we could see meaningful price drops once the first few are approved. That's the difference between paying $300–400/month and paying $100–150/month.
The system is preparing for generic entry. The question is no longer if, but when.
Novo Nordisk Cuts Wegovy to US$149/Month in the US — What It Signals for Canada
In a clear defensive move ahead of generic competition, Novo Nordisk has launched aggressive promotional pricing for Wegovy in the United States — offering the oral pill at US$149/month for the 1.5 mg and 4 mg doses through NovoCare and select telehealth providers like Ro and WeightWatchers. The offer runs through August 31, 2026, after which the 4 mg dose increases to US$199/month.
Why this matters for Canada: While this pricing is US-only, the move tells us something important. With nine generic semaglutide applications under Health Canada review, Novo Nordisk is clearly trying to lock in patients before cheaper alternatives arrive — and they're willing to slash prices dramatically to do it. Canadian patients are still paying $300–400/month at retail pharmacies with no equivalent discount program.
The competitive pressure is building. When generics arrive in Canada, we'll likely see similar or greater price drops here.
Compare current Canadian prices →
Zepbound's $50/Month Medicare Pricing Now in Effect in the US
A quick update on a story we've been tracking: Eli Lilly's agreement with the US government to offer Zepbound (tirzepatide) at no more than US$50/month for Medicare beneficiaries took effect this month, starting April 1, 2026. That's the same medication sold as Mounjaro for diabetes.
Meanwhile, Canadian patients are still paying $300–570/month depending on the drug, dosage, and province — with no public plan coverage for weight management.
The US pricing move adds to a global trend of pharmaceutical companies cutting prices under competitive pressure. For Canadians, the takeaway is clear: affordable GLP-1 access is coming, but we're not there yet. Generic semaglutide remains the nearest milestone for meaningful price relief in Canada.
This Week in Brief
- Ozempic now drives 8.5% of Canada's public drug cost growth — A single medication representing that much of total spending growth shows why generics can't come soon enough. Read more →
- Aspen Pharmacare targets Canada entry Q3 2026 — South Africa's pharmaceutical giant aims to launch generic semaglutide in Canada by summer, using Canada as a reference market for emerging regions. Read more →
- Dr. Reddy's has been under Health Canada review since 2024 — Among the earliest generic filers, the India-based manufacturer submitted its application in early 2024. Read more →
- Canadian semaglutide sales hit $3.5 billion in 2025 — IQVIA data shows the size of the market that generics are about to disrupt. Read more →
In Case You Missed It
- Health Canada approved Rybelsus for heart disease prevention — (January 2026) — The oral semaglutide tablet now has an expanded indication to reduce cardiovascular risk in adults with Type 2 diabetes. It's the first oral GLP-1 in Canada with this dual benefit. Read more →
Generic Semaglutide in Canada — Where Things Stand
| Status | Detail |
|---|---|
| Applications under review | 9 |
| Key companies | Apotex (3), Sandoz, Teva, Taro, Aspen, Dr. Reddy's, Vimy Pharma |
| Expected timeline | Q3 2026 (summer/fall) |
| Expected price | $100–150/month (down from $300–400) |
| Patent status | ✓ Expired (data exclusivity ended Jan 5, 2026) |
Get notified when generic prices go live
We’ll send one email the moment generic semaglutide prices are listed at Canadian pharmacies. No spam.
Get notified when generic semaglutide becomes available in Canada
Expected Q3 2026 — be the first to know